These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 23383426)

  • 1. Strategies to address low drug solubility in discovery and development.
    Williams HD; Trevaskis NL; Charman SA; Shanker RM; Charman WN; Pouton CW; Porter CJ
    Pharmacol Rev; 2013 Jan; 65(1):315-499. PubMed ID: 23383426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
    Elder DP; Holm R; Diego HL
    Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of oral bioavailability enhancing formulations during drug discovery.
    Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
    Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the solubility parameter concept to assist with oral delivery of poorly water-soluble drugs - a PEARRL review.
    Jankovic S; Tsakiridou G; Ditzinger F; Koehl NJ; Price DJ; Ilie AR; Kalantzi L; Kimpe K; Holm R; Nair A; Griffin B; Saal C; Kuentz M
    J Pharm Pharmacol; 2019 Apr; 71(4):441-463. PubMed ID: 29978475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Trends in Self-Emulsifying Drug Delivery Systems (SEDDSs) to Enhance the Bioavailability of Poorly Water-Soluble Drugs.
    Karwal R; Garg T; Rath G; Markandeywar TS
    Crit Rev Ther Drug Carrier Syst; 2016; 33(1):1-39. PubMed ID: 27279337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid dispersions: a review.
    Dhirendra K; Lewis S; Udupa N; Atin K
    Pak J Pharm Sci; 2009 Apr; 22(2):234-46. PubMed ID: 19339238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs.
    Cerpnjak K; Zvonar A; Gašperlin M; Vrečer F
    Acta Pharm; 2013 Dec; 63(4):427-45. PubMed ID: 24451070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral lipid-based formulations.
    Hauss DJ
    Adv Drug Deliv Rev; 2007 Jul; 59(7):667-76. PubMed ID: 17618704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs.
    Maleki A; Kettiger H; Schoubben A; Rosenholm JM; Ambrogi V; Hamidi M
    J Control Release; 2017 Sep; 262():329-347. PubMed ID: 28778479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.
    Williams HD; Ford L; Lim S; Han S; Baumann J; Sullivan H; Vodak D; Igonin A; Benameur H; Pouton CW; Scammells PJ; Porter CJH
    J Pharm Sci; 2018 Jan; 107(1):203-216. PubMed ID: 28549907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into the Development of Dissolution Media for BCS Class II Drugs: A Review from Quality Control and Prediction of In Vivo Performance Perspectives.
    Wu C; Liu Y; He Z; Sun J
    Curr Drug Deliv; 2016; 13(7):1004-1020. PubMed ID: 26725724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 50years of oral lipid-based formulations: Provenance, progress and future perspectives.
    Feeney OM; Crum MF; McEvoy CL; Trevaskis NL; Williams HD; Pouton CW; Charman WN; Bergström CAS; Porter CJH
    Adv Drug Deliv Rev; 2016 Jun; 101():167-194. PubMed ID: 27089810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM; Beig A; Carr RA; Spence JK; Dahan A
    Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs.
    Nyamba I; Sombié CB; Yabré M; Zimé-Diawara H; Yaméogo J; Ouédraogo S; Lechanteur A; Semdé R; Evrard B
    Eur J Pharm Biopharm; 2024 Nov; 204():114513. PubMed ID: 39313163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug precipitation inhibitors in supersaturable formulations.
    Xu S; Dai WG
    Int J Pharm; 2013 Aug; 453(1):36-43. PubMed ID: 23680727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
    Pouton CW
    Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.